Coya Therapeutics ( NASDAQ: COYA ) has promoted Arun Swaminathan as its new chief executive officer, effective November 1, 2024. Swaminathan, who previously served as chief business officer, was instrumental in executing Coya’s licensing transaction with Dr. Reddy’s Laboratory in December 2023 that could be worth up to $700M if all milestones are met.
Source: Press Release More on Coya Therapeutics Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts Coya stock tumbles 23% on mixed results from Alzheimer's study Seeking Alpha’s Quant Rating on Coya Therapeutics Historical earnings data for Coya Therapeutics.